Clin Cancer Res: Professor Chen Ming's team found that 50Gy is more suitable for concurrent chemoradiotherapy in inoperable esophageal squamous cell carcinoma (ESCC).

Patients with inoperable esophageal squamous cell carcinoma (ESCC) are often treated with concurrent chemoradiotherapy (CCRT), and the optimal dose of radiotherapy remains unclear

Patients with inoperable esophageal squamous cell carcinoma (ESCC) are often treated with concurrent chemoradiotherapy (CCRT), and the optimal dose of radiotherapy remains unclear

Patients with pathologically confirmed stage IIA-IVA ESCC were randomized 1:1 to receive either 60 Gy or 50 Gy of conventionally fractionated (tumor and regional lymph node) radiotherapy

Patients with pathologically confirmed stage IIA-IVA ESCC were randomized 1:1 to receive either 60 Gy or 50 Gy of conventionally fractionated (tumor and regional lymph node) radiotherapy

From May 10, 2013 to May 16, 2017, a total of 324 patients in 22 centers were randomly assigned to receive either 60 Gy (experimental group, n = 161) or 50 Gy (control group (n = 163).

The median follow-up time of 319 patients was 34.

The 1-, 2-, and 3-year OS rates in the two groups were 83.

The 1-, 2-, and 3-year OS rates in the two groups were 83.

The 1-, 2-, and 3-year PFS rates in the two groups were 71.

The 1-, 2-, and 3-year PFS rates in the two groups were 71.

Any progression rates were 46.

Any progression rates were 46.

Adverse events of grade 3 or higher occurred in 54.

Adverse events of grade 3 or higher occurred in 54.

In conclusion, the study showed that 60Gy and 50Gy concurrent chemoradiotherapy had comparable efficacy in the treatment of inoperable ESCC patients, but the 60Gy group had a higher incidence of severe pneumonia, so 50Gy might be a better recommended dose

In conclusion, the study showed that 60Gy and 50Gy concurrent chemoradiotherapy had comparable efficacy in the treatment of inoperable ESCC patients, but the 60Gy group had a higher incidence of severe pneumonia, so 50Gy might be a better recommended dose

Original source:

Original source:

Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z, Yang X, Liu L, He H, Liao Z, Guan N, Kong Y, Wang W, Chen J, He H, Qiu G, Zeng M , Pu J, Hu W, Bao Y, Liu Z, Ma J, Jiang H, Du X, Hu J, Zhuang T, Cai J, Huang J, Tao H, Liu Y, Liang X, Zhou J, Tao G, Zheng X, Chen M.
A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
Clin Cancer Res.
2022 Feb 18:clincanres.
3843.
2021.
doi: 10.
1158/1078-0432.
CCR-21-3843.
Epub ahead of print.
PMID: 35190815.

Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z, Yang X, Liu L, He H, Liao Z, Guan N, Kong Y, Wang W, Chen J, He H, Qiu G, Zeng M , Pu J, Hu W, Bao Y, Liu Z, Ma J, Jiang H, Du X, Hu J, Zhuang T, Cai J, Huang J, Tao H, Liu Y, Liang X, Zhou J, Tao G, Zheng X, Chen M.
A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
Clin Cancer Res.
2022 Feb 18:clincanres.
3843.
2021.
doi: 10.
1158/1078-0432.
CCR-21-3843.
Epub ahead of print.
PMID: 35190815.


Leave a message here